Richard M. Stone, MD

Articles

Dr. Stone on the Promise of Menin Inhibitors in AML

March 17th 2021

Richard M. Stone, MD, discusses the promise of menin inhibitors in patients with acute myeloid leukemia.

Dr. Stone on Combinations With Venetoclax in AML

May 2nd 2020

Richard M. Stone, MD, director of the Adult Leukemia Program, Dana-Farber Cancer Institute, and professor of medicine, Harvard Medical School, discusses combinations with venetoclax (Venclexta) in acute myeloid leukemia (AML).

Dr. Stone on Monitoring Patients With AML

November 15th 2017

Richard M. Stone, MD, director of the Adult Leukemia Program, Dana-Farber Cancer Institute, and professor of medicine, Harvard Medical School, discusses monitoring patients with acute myeloid leukemia.

Dr. Stone on MRD in Hematologic Malignancies

October 27th 2017

Richard M. Stone, MD, director of the Adult Leukemia Program, Dana-Farber Cancer Institute, and professor of medicine, Harvard Medical School, discusses minimal residual disease (MRD) in hematologic malignancies.

Dr. Stone Discusses Monitoring MRD in AML

October 11th 2017

Richard M. Stone, MD, director of the Adult Leukemia Program, Dana-Farber Cancer Institute, and professor of medicine, Harvard Medical School, discusses monitoring minimal residual disease in acute myeloid leukemia.

Dr. Richard M. Stone on the Genetic Landscape in AML

October 6th 2016

​Richard M. Stone, MD, chief of staff, program director, adult leukemia, institute physician, professor of medicine, Harvard Medical School, Dana-Farber Cancer Institute, discusses what is currently understood regarding the genetic landscape in acute myeloid leukemia (AML).